New chemo combo with immunotherapy and radiation for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic cancer through a biopsy or cell sample.
- Your daily activities are not severely limited (ECOG score 0-2).
- Your cancer is locally advanced, meaning it has not spread to distant organs but is too close to major blood vessels to be removed by surgery.
- You have not received any prior cancer treatment for this condition.
- You are willing and able to give written permission to be in the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (NALIRIFOX plus immunotherapy) followed by radiation, compared to NALIRIFOX alone, as a way to shrink pancreatic tumors that haven't spread and make them removable. It's for people who haven't had any previous cancer treatment.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of chemotherapy (Nal-IRI, 5-FU, leucovorin), an immunotherapy drug (PD-L1 inhibitor), and a targeted anti-angiogenic pill, with or without radiation (SBRT), as a second-line treatment for people with metastatic pancreatic cancer that has progressed after first-line therapy.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.